256 related articles for article (PubMed ID: 33935757)
1. RIPK2 as a New Therapeutic Target in Inflammatory Bowel Diseases.
Honjo H; Watanabe T; Kamata K; Minaga K; Kudo M
Front Pharmacol; 2021; 12():650403. PubMed ID: 33935757
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the development of RIPK2 modulators for the treatment of inflammatory diseases.
Pham AT; Ghilardi AF; Sun L
Front Pharmacol; 2023; 14():1127722. PubMed ID: 36959850
[TBL] [Abstract][Full Text] [Related]
3. RIPK2 NODs to XIAP and IBD.
Topal Y; Gyrd-Hansen M
Semin Cell Dev Biol; 2021 Jan; 109():144-150. PubMed ID: 32631784
[TBL] [Abstract][Full Text] [Related]
4. RIPK2: a promising target for cancer treatment.
You J; Wang Y; Chen H; Jin F
Front Pharmacol; 2023; 14():1192970. PubMed ID: 37324457
[TBL] [Abstract][Full Text] [Related]
5. Joint NOD2/RIPK2 signaling regulates IL-17 axis and contributes to the development of experimental arthritis.
Vieira SM; Cunha TM; França RF; Pinto LG; Talbot J; Turato WM; Lemos HP; Lima JB; Verri WA; Almeida SC; Ferreira SH; Louzada-Junior P; Zamboni DS; Cunha FQ
J Immunol; 2012 May; 188(10):5116-22. PubMed ID: 22491249
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a novel RIPK2 inhibitor for the treatment of inflammatory bowel disease.
Lai Y; Wang X; Sun X; Wu S; Chen X; Yang C; Zhang W; Yu X; Tong Y; Ma F; Zheng H; Zhang X; He S
Biochem Pharmacol; 2023 Aug; 214():115647. PubMed ID: 37315817
[TBL] [Abstract][Full Text] [Related]
7. Receptor Interacting Ser/Thr-Protein Kinase 2 as a New Therapeutic Target.
Rivoal M; Dubuquoy L; Millet R; Leleu-Chavain N
J Med Chem; 2023 Nov; 66(21):14391-14410. PubMed ID: 37857324
[TBL] [Abstract][Full Text] [Related]
8. Receptor-interacting protein kinase 2 contributes to host innate immune responses against Fusobacterium nucleatum in macrophages and decidual stromal cells.
Park JY; Lee TS; Noh EJ; Jang AR; Ahn JH; Kim DY; Jung DH; Song EJ; Lee YJ; Lee YJ; Lee SK; Park JH
Am J Reprod Immunol; 2021 Jul; 86(1):e13403. PubMed ID: 33580557
[TBL] [Abstract][Full Text] [Related]
9. Dysregulation of Intestinal Epithelial Cell RIPK Pathways Promotes Chronic Inflammation in the IBD Gut.
Garcia-Carbonell R; Yao SJ; Das S; Guma M
Front Immunol; 2019; 10():1094. PubMed ID: 31164887
[TBL] [Abstract][Full Text] [Related]
10. The potent and selective RIPK2 inhibitor BI 706039 improves intestinal inflammation in the TRUC mouse model of inflammatory bowel disease.
Ermann J; Matmusaev M; Haley EK; Braun C; Jost F; Mayer-Wrangowski S; Hsiao P; Ting N; Li L; Terenzio D; Chime J; Lukas S; Patnaude L; Panzenbeck M; Csordas D; Zheng J; Mierz D; Simpson T; King FJ; Klimowicz AP; Mbow ML; Fine JS; Miller CA; Fogal SE; Byrne FR
Am J Physiol Gastrointest Liver Physiol; 2021 Nov; 321(5):G500-G512. PubMed ID: 34494462
[TBL] [Abstract][Full Text] [Related]
11. Postbiotics for NOD2 require nonhematopoietic RIPK2 to improve blood glucose and metabolic inflammation in mice.
Cavallari JF; Barra NG; Foley KP; Lee A; Duggan BM; Henriksbo BD; Anhê FF; Ashkar AA; Schertzer JD
Am J Physiol Endocrinol Metab; 2020 Apr; 318(4):E579-E585. PubMed ID: 32101030
[TBL] [Abstract][Full Text] [Related]
12. Assaying RIPK2 Activation by Complex Formation.
Steinle H; Ellwanger K; Kufer TA
Methods Mol Biol; 2022; 2523():133-150. PubMed ID: 35759195
[TBL] [Abstract][Full Text] [Related]
13. RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems.
Kobayashi K; Inohara N; Hernandez LD; Galán JE; Núñez G; Janeway CA; Medzhitov R; Flavell RA
Nature; 2002 Mar; 416(6877):194-9. PubMed ID: 11894098
[TBL] [Abstract][Full Text] [Related]
14. Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium.
Pedersen G
Dan Med J; 2015 Jan; 62(1):B4973. PubMed ID: 25557335
[TBL] [Abstract][Full Text] [Related]
15. ATG16L1 negatively regulates RICK/RIP2-mediated innate immune responses.
Honjo H; Watanabe T; Arai Y; Kamata K; Minaga K; Komeda Y; Yamashita K; Kudo M
Int Immunol; 2021 Jan; 33(2):91-105. PubMed ID: 32909611
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors.
Canning P; Ruan Q; Schwerd T; Hrdinka M; Maki JL; Saleh D; Suebsuwong C; Ray S; Brennan PE; Cuny GD; Uhlig HH; Gyrd-Hansen M; Degterev A; Bullock AN
Chem Biol; 2015 Sep; 22(9):1174-84. PubMed ID: 26320862
[TBL] [Abstract][Full Text] [Related]
17. Expression of TRAF6 and pro-inflammatory cytokines through activation of TLR2, TLR4, NOD1, and NOD2 in human periodontal ligament fibroblasts.
Tang L; Zhou XD; Wang Q; Zhang L; Wang Y; Li XY; Huang DM
Arch Oral Biol; 2011 Oct; 56(10):1064-72. PubMed ID: 21457942
[TBL] [Abstract][Full Text] [Related]
18. Expression and activity of NOD1 and NOD2/RIPK2 signalling in mononuclear cells from patients with rheumatoid arthritis.
Franca R; Vieira SM; Talbot J; Peres RS; Pinto LG; Zamboni DS; Louzada-Junior P; Cunha FQ; Cunha TM
Scand J Rheumatol; 2016 Jan; 45(1):8-12. PubMed ID: 26202066
[TBL] [Abstract][Full Text] [Related]
19. Emerging views of mitophagy in immunity and autoimmune diseases.
Xu Y; Shen J; Ran Z
Autophagy; 2020 Jan; 16(1):3-17. PubMed ID: 30951392
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia.
Duggan BM; Foley KP; Henriksbo BD; Cavallari JF; Tamrakar AK; Schertzer JD
Sci Rep; 2017 May; 7(1):1578. PubMed ID: 28484277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
